G-protein-coupled receptors are the most tractable class of protein targets for small molecule drug design. Sequencing of the human genome allied to bio-informatic analysis has identified a large number of putative receptors for which the natural ligands remain undefined. A range of currently employed and developing strategies to identify ligands that interact with these orphan receptors and to validate them as drug targets are described and discussed.
Introduction
As well as comprising one of the largest gene families, G-protein-coupled receptors (GPCRs) have been the most widely and successfully targeted set of proteins for small-molecule drug design by the pharmaceutical industry [l-61. T h e reasons for this include that because GPCRs are trans-plasma-membrane proteins that bind and respond to extracellular hormones, neurotransmitters and neuromodulators, novel synthetic ligands do not have to be sufficiently lipophillic to cross the external membrane of the cell efficiently. Furthermore, as the seven transmembrane element topography of GPCR family members is likely to result in them sharing highly conserved structures in the core transmembrane domain then the extensive knowledge base of pharmacophore structures that bind GPCRs with good affinity is likely to be widely applicable. GPCRs are thus considered highly tractable potential therapeutic targets [l-61. Even prior to extensive genome analysis, the significant sequence similarity in the transmembrane regions allowed rapid 'cloning by homology' of novel GPCR sequences and this provided a large number of potentially interesting, but poorly validated, targets for therapeutic intervention. However, the ligands for novel GPCRs identified by such strategies were undefined. Such GPCRs are designated orphans. Informatics and sequence alignments allowed reasonable predictions of likely ligands for a number of the earliest cloned orphan GPCRs. For example, the first decoded orphan GPCR was the product of the G21 gene [7] . As this GPCR was isolated by screening a DNA library with a probe derived from the sequence of the P,-adrenoceptor it was clearly highly related and thus likely to encode a receptor for another catecholamine or a closely related small molecule. G21 was rapidly shown to encode the S-hydroxytryptamine,, receptor [7] . However, lower relatedness of GPCRs identified from analysis of EST and genomic sequencing efforts means that, although such informatic analysis can be helpful, it is unlikely to be sufficient, in isolation, to allow identification of partner ligands for many of the remaining orphan GPCRs.
Molecular genetic indications of ligands for orphan GPCRs
Tissue distribution of orphan GPCRs can be assessed rapidly with selective oligonucleotide probes capable of binding with high affinity to mRNA encoding the GPCR polypeptide. Widely used techniques include various automated and high-throughput forms of reverse transcription coupled to PCR and basic Northern blotting/dot blotting of mRNA isolated from a range of tissues. There is also growing application of microarray technologies using gene chips designed to report the presence of each member of the GPCR family in a genome.
Mice from which expression of a particular GPCR has been eliminated by targeted gene disruption can also provide physiological and phenotypic clues to the identity of naturally occurring partner ligands. When such knockouts are combined with replacement expression of an easily detectable marker, such as P-galactosidase, further information on the patterns and networks 
Screening for ligands at orphan GPCRs
Two distinct philosophies dominate efforts in this area. T h e first of these considers the key initial objective to identify the natural ligand(s) for the GPCR. A key issue is that almost all endogenous ligands for GPCR act as agonists. Thus such ligands will produce a response upon addition to a cell or tissue expressing a cognate GPCR. T h e second philosophy takes the pragmatic view that identification of a ligand is paramount and that initially it is not important whether this ligand is relevant endogenously or if it is an agonist or an antagonist/inverse agonist. T h e benefit of this view is that libraries of synthetic small molecules will contain a much greater number of antagonist/inverse agonist rather than agonist structures. This reflects the fact that constraints on binding of an antagonist, which simply has to occlude the binding site, will be significantly less than for an agonist that has to bind and produce activation of the GPCR. However, as many GPCRs are relatively silent in the absence of agonist ligands, there is little opportunity to observe the binding of an antagonist/inverse agonist to such GPCRs. Mutagenic strategies that enhance the signal-transducing properties of GPCRs in the absence of an agonist have been developed based upon early experiments that showed enhanced agonist-independent or constitutive activity in GPCRs mutated close to the interface between the third intracellular loop and transmembrane helix VI [lo] . Synthetic molecules displaying inverse agonism [ 1 1-1 41 can suppress this activity. GPCR-selective ligands with these properties can then be used in competition binding or functional assays to identify further synthetic chemicals or the natural ligands. Such molecules can also be given to animals to observe phenotypes and actions associated with blocking the access of endogenous ligand to the GPCR and thus provide further insights into the identity of the endogenous ligands and to efforts to validate the GPCR as a therapeutic target. However, one criticism often directed at this approach is that it generally requires mutagenesis of the GPCR and that this might alter the details of receptor pharmacology.
Screening for agonist ligands at orphan GPCRs Elevation of intracellular Ca2+ concentration
If lack of information on agonist ligands was not a sufficient hurdle, until recently bio-infomatic approaches have not been very successful in determining the likely G-protein-coupling specificity or selectivity of individual GPCRs [15] . Four distinct families of heterotrimeric G-proteins are known and these transduce information to a number of distinct secondary messenger regulators. T h u s an aim of many functional screens for agonists of orphan GPCRs is to channel information from a diverse set of GPCRs to a common end point such that a single, robust and, if possible, automated screen can be constructed. Perhaps surprisingly given that all G-protein a subunits interact with and release G-protein ply complexes that are themselves inherent signal-transducing complexes, end points that monitor G-protein subunit dissociation have not been widely employed. Recently, however, a fluorescence resonance energy transfer (FRET)-based assay has been introduced that is designed on this principle T h e G-proteins Ga,, and Gal,, although displaying a very restricted pattern of endogenous expression [ 171, have been shown able to couple many GPCRs that do not activate other members of the Ga, G-protein family to activation of phospholipase Cpl [18] . This results in the hydrolysis of inositol-containing phospholipids and the subsequent elevation of [Ca2+],. However, although these are sometimes referred to as 'universal' G-proteins [19] there are a number of examples of GPCRs that apparently fail to couple. Mutagenesis of these G-proteins can further expand the range of GPCRs that couple to them [20] . A further generic strategy to ensure effective G-protein coupling and signal transduction takes advantage of the fact that the extreme C-terminus of a G-protein a subunit is a key contact site for GPCRs [21, 22] , whereas sequences required to define the effector enzymes that are regulated lie further upstream. Alteration of the last few amino acids of the C-terminus of a G-protein from one subfamily to those from a separate G-protein family alters the subsets of GPCRs that can interact productively with the G-protein [23-251. Thus, a chimaeric G a protein that consists of virtually the full length of the phospholipase Cpl regulator Ga, but with re-(CCa'+lJ [161.
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placement of the C-terminal five amino acids with those from the sequences of Ga, or Gas allows GPCRs that would couple normally to the inhibition or elevation of CAMP to elevate [Ca"], [23] . In screens for agonists at orphan GPCRs it is common to transfect a cocktail of Gal,,l5 and various G a chimaerae that have the backbone of Ga, into cells expressing the GPCR to provide the greatest chance of generating a signal. Other screens monitor end points that are well downstream of GPCR activation and include the regulation of reporter genes driven by generation of signals coupled to transcriptional control [26] or to mitogenic signalling [27] . No matter what the end point, in screens for agonists at orphan GPCRs the co-expression of such chimaeric and universal G-proteins is still used routinely to enhance the detection of potential hits.
Protein-translocation assays
Emerging technologies for identification of agonists in orphan GPCR screens employ assays in which activation of the GPCR results in cellular translocation of a reporter polypeptide. This might be the GPCR itself as agonist-induced internalization is a commonly observed phenotype. It is common to tag orphan GPCRs with reporters that can be visualized, such as green fluorescent protein (GFP), to confirm that the orphan does indeed get expressed and is appropriately targeted to the plasma membrane [28, 29] . Thus, the translocation of the GPCR in an agonist screen from cell surface to internal acidic endosomes is a useful hint that the ligand is probably an agonist at the GPCR [28-301. Similar screens can be established by tagging other proteins that translocate in response to GPCR occupancy by an agonist. Currently the most widely used is arrestin-3 [31]. T h e majority of GPCRs become phosphorylated in their C-terminal region in response to agonist binding and this provides a high-affinity binding site for an arrestin [31, 32] . Both arrestin-2 and arrestin-3 are widely expressed and are generally cytoplasmic proteins in the absence of GPCR activation. Agonist activation of a GPCR causes a translocation of the arrestin to the plasma membrane and, depending upon the affinity of the interaction, the arrestin can be co-internalized with the GPCR [33, 34] . This approach has been applied directly to the identification of endogenous ligands for orphan GPCRs [35] . Although there are exceptions [36] , arrestin-3 generally displays at least as high an affinity of interaction with GPCRs as arrestin-2 and thus GFP-tagged forms of this arrestin are the most widely used. Algorithms that recognize the alterations in cellular distribution of the GPCR or the arrestin have allowed such ' high-content screens' to be incorporated in imaging systems capable of handling microtitre plates [37, 38] . Conceptually, translocations of a wide range of proteins can be used in such assays, but the biological basis and universality of the arrestin assay is currently the best established. For all of these assays, there are potential limitations on the identification of ligands with partial agonist activity. Agonists with low efficacy frequently fail to cause internalization of a GPCR or the translocation of reporter polypeptides such as an arrestin [39] . However, in screens for endogenous ligands this is unlikely to represent a major concern as such ligands are generally highly efficaceous.
Screening for antagonisdinverseagonist ligands at GPCRs
Screening for antagonistlinverse-agonist ligands at orphan GPCRs inherently offers a different set of challenges. Although a number of GPCRs, including a number of interesting receptors encoded by viral genomes [40, 41] , display a high level of constitutive activity that can be suppressed by ligands that function as inverse agonists, this is often too limited to utilize directly. Furthermore, suppression of [Ca"+Ii elevation is not a suitable end point to assess as Ca2+ released via the constitutive activity of a GPCR is rapidly sequestered again into intracellular stores. This generally eliminates the use of Gal,),, and the chimaeric G-proteins based on the backbone of Ga,.
T w o generic and potentially interrelated approaches have been used. As mutations of GPCRs at the interface of transmembrane helix VI and the third intracellular loop frequently enhance the agonist-independent activity of a GPCR [42, 43] . They also elevate hydrolysis of G T P loaded by the constitutive activity of a GPCR as well as that loaded by agonist binding [48] . Thus addition of a recombinant R G S to such assays markedly increases the basal signal derived from constitutive GPCR activation and greatly increases the window of activity that can be suppressed by an inverse agonist [48] . An alternative approach with high sensitivity to monitor the constitutive activity of GPCRs is the use of amphibian melanophores. Because dispersion of pigment in these cells is altered in response to second-messenger regulation [49, 50] , they provide a readout that is well suited to high-throughput screening for both agonist and antagonist/inverse-agonist ligands. A second feature of many GPCR mutations that enhance constitutive activity is that they reduce the stability of the receptor polypeptide when it is not bound by a ligand. T h e presence of a ligand, no matter what its efficacy, suppresses this effect [51, 52] . Thus, in an intact cell assay, such mutant GPCRs are up-regulated by prolonged exposure to a ligand. Linkage of a GPCR to a suitable visual reporter, such as G F P [52, 53] , or an enzyme activity that is easy to measure, such as Renilla luciferase [54] , allows identification of novel ligands [51] .
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